Ind-Swift Labs. (INDSWFTLAB)

FairStock Score: 36/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Debt/Equity of 0.02 gives strong balance-sheet resilience
• Piotroski F-Score of 7/9 points to recent financial improvement
• ROE of 24.39% is strong on the surface, and P/B of 1.19 is close to book value
• Sales growth of 17.12% shows the business is expanding
• Latest quarter net profit of ₹10 Cr on ₹151 Cr sales indicates some positive momentum

Concerns

• ROCE of just 0.78% shows core operating returns are far too low for a value investment
• Profit growth of 371.85% is likely distorted by a low base or non-operating factors and is not dependable
• Zero dividend and moderate promoter holding leave minority shareholders reliant on management execution
• FairStock Score of 33/100 flags the stock as risky, and the 52-week range ₹87.15-₹320.50 shows high volatility

AI Analysis

At first glance, Ind-Swift Labs looks like a classic Graham low-P/B situation: price ₹137.85, book value ₹116.32, P/B 1.19, and almost no debt. But the first rule is to never confuse a cheap price with value. The reported numbers have improved on paper — sales up 17.12%, profits up 371.85% — yet the ROCE is a terrible 0.78%. That single figure tells me the core business is not earning a satisfactory return on capital employed. A ROE of 24.39% alongside such a low ROCE is a warning: part of the profit may be coming from non-operating or volatile sources, not from durable business economics. As Graham said, the investor must demand a margin of safety. Here the safety is thin because the capital is cheap only if profits can be sustained. The debt/equity of 0.02 and Piotroski score of 7/9 do suggest a cleaner balance sheet and some improving metrics. Promoter holding at 43% is moderate, but there is zero dividend, so shareholders must depend entirely on growth. At a P/E of 25, the market is not giving the stock away. The 52-week range of ₹87.15 to ₹320.50 shows how unpredictable the earnings momentum has been. Overall, this is a possible turnaround, not a compounder. I would wait for ROCE to improve materially and for quarterly profit to be sustained before calling this an opportunity.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer